Intradermal delivery of vaccine nanoparticles using hollow microneedle array generates enhanced and balanced immune response

Niu, Lin; Chu, Leonard Y.; Burton, Scott A.; Hansen, Kristen J.; Panyam, Jayanth

doi:10.1016/j.jconrel.2018.12.026

Cited by 131 publications

(89 citation statements)

References 47 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…16 Niu et al found that intradermal delivery by hollow microneedle array creates a sustained release depot in the skin and can create a burst transit through draining lymph nodes. 17 Strong support to the application value of HMNs was given when researchers found that HMN array transfer resulted in a signicantly higher immune response compared with the intramuscular injection method. A case study in 2018 reported that use of the HMN strategy resulted in a "steady state" of insulin plasma concentration that mimicked a multiple-dose regimen.…”

Section: Types Of Microneedlesmentioning

confidence: 99%

Microneedles: a potential strategy in transdermal delivery and application in the management of psoriasis

2020

View full text Add to dashboard Cite

show abstract

Section: Types Of Microneedlesmentioning

confidence: 99%

Microneedles: a potential strategy in transdermal delivery and application in the management of psoriasis

2020

View full text Add to dashboard Cite

show abstract

“…Zhang et al showed that when MNs were used to deliver DNA vaccines, the gene expression and corresponding immune responses were greatly improved compared to the results of conventional needle injection. [36] Niu et al reported that the hollow MN-mediated intradermal delivery of the model antigen ovalbumin encapsulated in polymeric nanoparticles is a promising approach to improve the effectiveness of vaccine formulations. The group of Prausnitz, the pioneer of the MN-based device, developed a dissolving MN patch for the administration of the inactivated polio vaccine (IPV) with greater thermal stability than that of the conventional liquid IPV.…”

Section: Therapeutics and Beyondmentioning

confidence: 99%

“…Coated (33) Dissolving (34), (35), (37), (43) Swelling (35) Hollow (36) In vivo (mouse) In vitro [33,[35][36][37]43] [ 34] Nausea and vomiting Swelling In vivo [38] Obesity Dissolving In vivo (mouse) [40,41] Keloid scar Swelling Ex vivo [42] Vitamin K deficiency Dissolving In vitro [44] have been loaded into MNs and effectively administered both in vitro and in vivo. [42][43][44] The spectrum of substances proven to be compatible with MN technology is wide.…”

Section: Warts Coatedmentioning

confidence: 99%

“…Hollow MNs can also help overcome the skin barrier imposed by the SC and facilitate the transcutaneous delivery of a nanoparticle system. [36] Niu et al reported that the hollow MN-mediated intradermal delivery of the model antigen ovalbumin encapsulated in polymeric nanoparticles is a promising approach to improve the effectiveness of vaccine formulations. Similarly, promising results have been obtained in the case of HA-based dissolving MNs with high antigen content for intradermal vaccination.…”

Section: Therapeutics and Beyondmentioning

confidence: 99%

“…Coated (33) Dissolving (34), (35), (37), (43) Swelling (35) Hollow (36) In vivo (mouse) In vitro [33,[35][36][37]43] [ 34] Nausea and vomiting…”

Section: Warts Coatedmentioning

confidence: 99%

See 2 more Smart Citations

Polymeric Microneedle Arrays: Versatile Tools for an Innovative Approach to Drug Administration

Dardano

Battisti²,

Rea

et al. 2019

Advanced Therapeutics

View full text Add to dashboard Cite

Mainly designed and realized as a painless alternative to the hypodermic syringe, microneedle-based devices are currently approaching commercial market placement. The considerable academic and industrial investment in this technology is reflected by a multitude of papers published and patents registered every year, which is also a sign of a field in full fermentation. New materials and innovative methodologies are continuously exploited in search of the best performance at the lowest cost. For these reasons, an updated review, focused predominantly on the last year of scientific production, is a useful guideline in this rapidly changing panorama. This report provides a critical review of microneedle technologies presented in the very recent literature with a particular focus on those closest to the needs of the healthcare field. Although a few devices are already commercial, further effort is still needed to achieve complete clinical translation and therapeutic efficacy competitive with or superior to those of the devices used as standards and adopted by national health systems.

show abstract

Microarray Patches: Poking a Hole in the Challenges Faced When Delivering Poorly Soluble Drugs

Paredes

McKenna

Ramöller

et al. 2020

Adv Funct Materials

View full text Add to dashboard Cite

Poorly soluble drugs constitute more than 60% of currently marketed pharmaceuticals with over two‐thirds of promising new chemical entities failing to enter a clinical setting due to solubility issues. Although oral formulations have made some impact, alternative enhancement strategies for administration of such molecules are actively sought. Over the last decade, innovation on a global scale has enabled the expansion of the frontiers of microarray patches (MAPs) further than ever before. Initially designed to load low doses of hydrophilic and potent therapeutic agents, MAPs are now becoming a viable strategy for the immediate and long‐acting delivery of poorly soluble drugs through the skin. This together with the advantages of transdermal administration over the oral and parenteral routes, make of MAPs an appealing platform for the development of products with increased patient compliance. Undoubtedly, MAPs will soon become a readily available therapeutic alternative, and experts from academia, industry and regulatory bodies are working together aiming to facilitate the progression of MAPs toward safe and effective clinical use. This review aims to highlight the ability of MAPs to deliver poorly soluble actives, discuss the mechanisms behind in‐skin drug absorption, and evaluate the future direction of the field.

show abstract

Intradermal delivery of vaccine nanoparticles using hollow microneedle array generates enhanced and balanced immune response

Cited by 131 publications

References 47 publications

Microneedles: a potential strategy in transdermal delivery and application in the management of psoriasis

Microneedles: a potential strategy in transdermal delivery and application in the management of psoriasis

Polymeric Microneedle Arrays: Versatile Tools for an Innovative Approach to Drug Administration

Microarray Patches: Poking a Hole in the Challenges Faced When Delivering Poorly Soluble Drugs

Contact Info

Product

Resources

About